Gilead To Become Victim Of Own Success In Japan?
This article was originally published in PharmAsia News
Gilead Sciences is on a roll both globally and in Japan, where two of its key drugs for hepatitis C have been launched this year and the California-based company is planning to roll out other pipeline products, including in oncology. But the rapid sales growth for its HCV products is raising the specter of possible price cuts.
Register for our free email digests: